Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALLAS: Aflibercept 8mg in Treatment-naive PCV
NCT07389980Phase 3Recruiting
- Sponsor
- Yeungnam University College of Medicine
- Start
- Dec 2026
- Primary completion
- Nov 2028
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in polypoidal choroidal vasculopathy (PCV), sponsored by Yeungnam University College of Medicine. Planned start Dec 2026; status: recruiting.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT07389980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07389980.